Chile Submission Documents: Apostille and Spanish Translation Requirements
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The document chain for Chilean submissions has three high-frequency breakpoints: the manufacturer authorization letter (the written delegation from the foreign manufacturer to the registration holder), the apostille, and the Spanish translation. Chile is a party to the Convention Abolishing the Requirement of Legalisation for Foreign Public Documents, so foreign public documents circulate through the apostille rather than consular legalization; documents from non-party states must follow the consular legalization path.
GRZAN condenses the risk into one sentence: the product information must be identical word for word across four documents — the CFS, the authorization letter, the label and the technical file. A mismatch in the product name, model, manufacturer name or registration and listing number is the most common cause of deficiency notices, and re-obtaining authenticated documents typically takes weeks. Build the data once, control it centrally, and every downstream document inherits the same values. The cost asymmetry is decisive: centralized master data takes days to establish, while a single inconsistency discovered at review can push a submission back by an entire document cycle.
2. Legal basis
- Regulation on the control of medical products and devices | Decreto Supremo N° 825, de 1998 | 21 August 1999 | Article 21: imported devices must be accompanied by a certificate issued in the country of origin for export purposes, authorized by that country’s competent authority and duly legalized (debidamente legalizado).
- Same instrument | Article 26: controlled products must be clearly marked on the product or its packaging as having passed conformity verification, with the number assigned by the ISP.
- ISP procedure | prestación 9100003 (v3, 25 September 2025) | requires the certificate of free sale, the manufacturer’s letter recognizing the applicant, the quality system certificate and sterile batch certificates, all of which must be authenticated or apostilled.
- ISP technical guidance | ANDID/024 | the definition of the authorized representative or registration holder presupposes a written delegation from the foreign manufacturer.
- Hague Convention | Convention Abolishing the Requirement of Legalisation for Foreign Public Documents | Chile is a party state | foreign public documents circulate through the apostille.
3. Expert insights
Insight 1: the apostille authenticates the signature and seal — not the truth of the content.
Many companies assume that an apostille exempts a document from substantive scrutiny. In fact it only certifies the identity of the signatory and the authenticity of the seal; the correctness of the document’s content remains the responsibility of the applicant. Inconsistent product information therefore does not disappear because the apostille has been obtained. The apostille answers whether the document is genuine; the review still asks whether the document is right, and only disciplined master data can make it right consistently. Plan authentication and content verification as two separate gates on the same document, and close neither gate on the strength of the other.
Insight 2: the scope of documents requiring authentication is broader than most teams expect.
The certificate of free sale, the manufacturer’s letter recognizing the applicant, the quality system certificate (ISO 13485 and similar) and sterile batch certificates all must be authenticated or apostilled. Companies routinely apostille only the CFS and then watch the remaining documents get returned. List every document the procedure names, confirm which ones originate abroad, and process the whole set in one batch rather than discovering the gap through rejection letters. Batch processing also saves fees, because notarial and consular steps price per document and per trip, and a second round doubles both.
Insight 3: translation is a compliance document, not a language service.
The Spanish version must match the source text, and it must also match the wording used on labels and instructions for use. GRZAN recommends building a multilingual master data table for product name, model, manufacturer name and address, and intended use, with every document drawing its values from that table. This is the most effective engineering measure against word-for-word inconsistency, because translators are no longer making choices — they are copying controlled values. The table itself becomes an auditable record: when a value changes, one cell updates and every dependent document is flagged for review at once.
Insight 4: authentication lead time is the hidden critical path in the schedule.
Apostilles and consular legalizations involve notaries, foreign affairs offices and embassies, and the cycle is usually counted in weeks (practical estimate). Placing this work after the product documentation engineering directly consumes the early-mover window. The correct approach is to start authentication in parallel with the dossier work, so that authenticated documents are sitting ready when the submission package is assembled.
4. Practical recommendations
- Build a product master data table covering name, model, manufacturer name and address, and intended use in the working languages, and draw every document’s values from that table.
- List the complete set of documents requiring an apostille: CFS, manufacturer authorization letter, quality system certificate and sterile batch certificates — process them in a single batch.
- Start the apostille work in parallel with documentation engineering; never queue it serially behind the dossier.
- Archive translations together with their source documents, marked with translator and date, so deficiencies can be located quickly.
- Make the authorization letter cover continuing obligations: not only the submission itself, but also change notifications, technical vigilance reporting and recall cooperation.
5. Verification checklist
- □ A product master data table in the working languages has been built and applied across all documents
- □ A complete list of documents requiring apostille has been produced
- □ The manufacturer authorization letter has been notarized and apostilled
- □ The authorization letter covers submission, changes, technical vigilance and recall cooperation
- □ Spanish translations have been checked word for word against the source text, labels and instructions for use
Regulatory information verified as of 29 October 2026.
GRZAN supports manufacturers entering the Chilean market with ISP registration pathways and classification strategy, including apostille chains, translation governance and master data control. For a feasibility assessment of your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us